Shaping better health
REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Adult Joint Formulary

COVID-19 rapid evidence summaries

Checked: not set yet by Next Review: not set yet

COVID-19 rapid evidence summaries

Rapid evidence summaries on 2 interleukin-6inhibitors, sarilumab and tocilizumab, in the treatment of adults with COVID-19 have been published.
 
Preliminary evidence suggests that sarilumab and tocilizumab are beneficial in adults with severe COVID‑19 who have either hypoxaemia with evidence of inflammation or are in the early stages of critical illness requiring respiratory support.   Benefit from these drugs may only be seen before or soon after organ support is started, when any developing organ dysfunction may be more reversible.  

See the following CAS alerts for details of eligibility and exclusion criteria:

CEM/CMO/2021/016

IL-6 inhibitors (tocilizumab or sarilumab) Interim Policy

New evidence on the effectiveness of COVID-19 treatments is being published at a rapid pace. The evidence reviews for tocilizumab and sarilumab will be updated over the coming weeks in light of emerging evidence.

 

The Department of Health and Social Care has published an interim position statement on use of inhaled budesonide for adults 50 years and over with COVID-19.  

 Interim Position Statement: Inhaled budesonide for adults (50 years and over) with COVID-19 

 

The Department of Health and Social Care has published a Rapid Policy Statement on use of casirivimab and imdevimab for patients hospitalised due to COVID-19: 

Casirivimab and imdevimab Interim Policy

CEM/CMO/2021/017